Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.
about
Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patientsCinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trialsCinacalcet versus standard treatment for chronic kidney disease: a protocol for a systematic review and meta-analysisEffects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysisCinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis.Pharmacotherapy of end-stage renal disease.Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism.Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled studyThe cost-effectiveness of drug therapies to treat secondary hyperparathyroidism in renal failure: a focus on evidence regarding paricalcitol and cinacalcet.A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM)Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT studyDecreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns.Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis.Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT studyTreatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism.Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D studyClinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.Comparison between calcitriol and calcitriol plus low-dose cinacalcet for the treatment of moderate to severe secondary hyperparathyroidism in chronic dialysis patients.Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?Efficacy of low-dose cinacalcet on alternate days for the treatment of secondary hyperparathyroidism in hemodialysis patients: a single-center study.Pharmacotherapy and interventional treatments for secondary hyperparathyroidism: current therapy and future challenges.Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?Diseases of the parathyroid gland in chronic kidney disease.Vascular and valvular calcification in chronic peritoneal dialysis patients.Cinacalcet: a pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease.Cinacalcet hydrochloride for the treatment of hyperparathyroidism.Safety and tolerability of paricalcitol in patients with chronic kidney disease.Paricalcitol and cardiorenal outcome: from the IMPACT study to clinical practice.Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism.Emerging drugs for secondary hyperparathyroidism.Advances in pharmacotherapy for secondary hyperparathyroidism.Cinacalcet and Clinical Outcomes in Dialysis.Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide.Cinacalcet: the chemical parathyroidectomy?Long-Term Hypoparathyroidism and Hypophosphatemia in Dialysis PatientsReversible bone pain and symmetric bone scan uptake in a dialysis patient treated with cinacalcet: a case report.Which vitamin D in CKD-MBD? The time of burning questions.Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.
P2860
Q24187385-834C306E-1A4B-44B4-A301-04466352290DQ26851487-320D03D9-F9AA-49A6-B860-D33309CFDC75Q28079300-240E787A-7386-4C75-9167-ADD3F31E3822Q28484646-5D4C8D16-DEFA-4AD6-82A2-FFE0E4E08199Q30251450-E66E18AF-0F36-4069-AC1F-B7B1F4E2DFE0Q33531889-0064F989-98A0-4A64-B3C1-464FCBD81279Q33571321-F4AB5FAB-7178-4A0F-A85F-C4D2BAC29746Q34293730-98848780-66C0-465E-AECF-D46715373BECQ34362759-0A016A24-7349-47A6-A541-0725C239EBE2Q34739121-F5879A83-393B-4CA2-9C7E-5A98D5BE455DQ35635182-E84B06FD-CCAD-4F04-BBE2-D5DBAD774D44Q35682192-193967BC-DCC4-437C-B591-DE249A45BEF0Q35920190-549DE44A-ED8B-47C4-A8F6-81FC79DEECBBQ35983513-AC54CCFE-B569-48A9-AE99-ACF58F64026DQ36121519-D6BE96BD-F2B2-4E4E-A080-74684F44BE22Q36129859-D729D269-1599-4D46-814B-FD9B0FB1E5BEQ36193227-BE220097-D8D7-4D80-84B1-832D9DB68DB0Q36199558-A8B1C5A9-999E-40A3-BA79-E426107AE665Q36432849-55E038DA-0520-4C49-A1CD-8BF14D78B28CQ36994093-59EF786F-72A0-4A7A-931E-5D296CD8A4FCQ37310824-662BBBA0-2C75-4DB0-89D4-4D9A80E56612Q37638757-2344B110-ED90-408B-8060-7B4CA660B892Q37807991-38546EB4-9559-4714-BD78-527193571DA2Q37891153-C665EE0B-5614-4D71-9F99-D525E51C1E50Q37912038-D44B1962-D755-412B-A80D-4EBF8382B8F0Q37914009-4944B741-4C30-446E-B1B4-E5BE56826B50Q37916534-A5A26BEB-6106-44D4-A924-9B123B5B4F54Q38085702-43D696A8-7D08-406A-9C8B-692B7B3DA35DQ38101995-C66ED34A-D8BB-446D-9F32-7833B33BC691Q38111948-E8096D54-9AA6-4F5A-8C8B-13A70AEB42F1Q38141236-A3A48F06-E160-4C36-BDA1-7D03324C2D35Q38363615-44108D57-2CA5-48B3-BD3A-CEA82EACF89EQ38544533-B0C25694-B36C-483E-80FC-F4B57C5A8F18Q38565049-24515437-5D6B-47E8-9BF4-49415770CA4EQ39374348-802E10FC-CCAA-448F-95F0-7D16432C4998Q39719456-AC34FDCD-8B52-4E98-BF45-33B2B7F0675DQ40479039-48648804-50F7-4428-AB68-BB4B89E290B0Q42194890-071058BC-0BB7-4BFC-A679-E97EE98DF1B4Q42562972-EE3F4BF3-CCA0-41B6-9937-033679EB28C0Q42683242-61722E39-582F-4E1F-8516-D87154488667
P2860
Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Cinacalcet HCl and concurrent ...... ne: the ACHIEVE study results.
@en
type
label
Cinacalcet HCl and concurrent ...... ne: the ACHIEVE study results.
@en
prefLabel
Cinacalcet HCl and concurrent ...... ne: the ACHIEVE study results.
@en
P2093
P2860
P921
P356
P1476
Cinacalcet HCl and concurrent ...... ne: the ACHIEVE study results.
@en
P2093
Chaim Charytan
Dalila B Corry
Kenneth Rappaport
Michael Roppolo
Steven Fishbane
Steven L Vicks
Stewart Turner
Warren B Shapiro
William G Goodman
Xiang Ling
P2860
P304
P356
10.2215/CJN.01040308
P577
2008-11-01T00:00:00Z